pH-Responsive Nanoparticles for Targeted Cancer Therapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current ERS inducers and immunoadjuvants used in cancer treatment face challenges such as off-target effects, toxicity to normal cells, poor water solubility, and non-selective uptake, leading to systemic immune activation and drug resistance, which limits their efficacy and safety.
Innovation Solution
A three-in-one nanoparticle formulation is developed, combining ERS inducers, nucleic acid immunomodulators, and immunoadjuvants with tumor-targeting peptides and aptamers, encapsulated in solid lipid nanoparticles with a pH-responsive coating to specifically deliver the therapeutic agents to cancer cells and immune cells, avoiding normal cell toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If ERS inducers are used to treat tumors, then antitumor effect is improved, but toxicity to normal cells increases
Solution Approach 1:
The patent segments the delivery system into nanoparticles that can be targeted to specific tumor locations, separating the antitumor action from normal tissue exposure. The nanoparticles are designed to accumulate preferentially in tumors through the EPR effect, delivering ERS inducers selectively to cancer cells while minimizing exposure to normal cells.
Solution Approach 2:
The patent introduces nanoparticles as an intermediary carrier between the ERS inducer and tumor cells. This intermediary system protects normal cells from direct exposure to toxic ERS inducers while facilitating their delivery to tumor cells, thereby resolving the contradiction between antitumor efficacy and normal tissue toxicity.
2Reliability
If immunoadjuvants are used to enhance immune response, then antitumor immune response is improved, but systemic inflammation increases
Solution Approach 1:
The patent segments the immune activation function by delivering immunoadjuvants through targeted nanoparticles to tumor sites rather than systemically. This localized delivery segments the immune response generation to occur primarily at the tumor location, reducing widespread systemic inflammation while maintaining effective antitumor immunity.
Solution Approach 2:
The patent applies local quality by concentrating immunoadjuvant activity at the tumor site through nanoparticle accumulation. The immunomodulatory effects are localized to the tumor microenvironment, creating strong local immune responses without provoking widespread systemic inflammation that would occur with intravenous administration of conventional immunoadjuvants.
3Reliability
If nucleic acid immunomodulators are used, then immune activation is improved, but stability in biological systems deteriorates
Solution Approach 1:
The patent uses nanoparticles as a protective intermediary carrier for nucleic acid immunomodulators. The nanoparticle shell protects the labile nucleic acids from degradation by nucleases in biological systems, maintaining their structural stability and immunomodulatory activity while still enabling them to activate immune responses effectively.
Solution Approach 2:
The patent employs a nanoparticle shell structure that encases and protects the nucleic acid immunomodulators. This shell acts as a protective barrier that prevents enzymatic degradation and maintains the stability of the nucleic acid payload throughout circulation and at the target site, resolving the stability issue while preserving immune activation capability.
4Adaptability or versatility
If ERS inducers are administered systemically, then tumor treatment coverage is improved, but off-target effects increase
Solution Approach 1:
The patent segments the distribution of ERS inducers from systemic circulation by using nanoparticles that accumulate preferentially in tumors. This segmentation allows broad tumor coverage through nanoparticle accumulation in various tumor sites while preventing off-target effects in normal tissues that would occur with direct systemic administration.
Solution Approach 2:
The nanoparticle serves as an intermediary that mediates between the ERS inducer and tumor cells, enabling widespread tumor treatment coverage through enhanced permeability and retention in various tumor locations while preventing direct contact with normal tissues that would cause off-target effects.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The nanoparticle formulation enhances targeted delivery of ERS inducers and immunotherapeutics to tumors, inhibiting cancer proliferation and metastasis while reducing systemic toxicity, thereby improving antitumor immune responses and overcoming drug resistance.
Implementation Method 1
the coating exhibits pH sensitivity under an acidic environment
Implementation Method 2
the target molecule of the surface of the nanoparticle core and the tumor microenvironment acid-detachable polymer of the outer layer form a space and charge barrier via the electrostatic interaction
Data Source
AI summary
Multifunctional nanoparticles incorporate an ERS inducer (p97 inhibitors) and immunotherapeutics (immune-modulating miR or aptamer plus immunoadjuvants) to address the poor aqueous solubility and toxicity associated with p97 inhibitors and immunotherapeutics while also enhancing the immune activation of these therapeutics. The nanoformulation offers several advantages, such as pH-sensitivity, self-detachable coating, active targeting, and intracellular localization in tumors, and has the potential to overcome the limitations of systemic administration, such as the degradation of nucleic acid therapeutics and toxicities associated with ERS inducer.